Abstract:The persistent transformation of quiescent hepatic stellate cells (HSCs) into myofibroblasts (MFs) and the excessive proliferation of MF-HSCs in the liver contribute to the pathogenesis of liver fibrosis, cirrhosis, and liver cancer. Glycolysis inhibition of MF-HSCs can reverse their MF phenotype and suppress their abnormal expansion. Here, we have developed vitamin A-derivative (VA) decorated PEG-PCL polymeric micelles to encapsulate the labile and hydrophobic camptothecin (CPT) and direct its active attack on HSCs, selectively inhibiting of HIF-1α and cellular glycolysis, ultimately repressing hepatic fibrogenesis. The obtained micelles exhibited a good stability, biocompatibility, pH sensitivity, and exceptional HSC-targetability, allowing an efficient accumulation of their carried CPT in acutely and chronically injured livers. On their intracellular release of CPT specifically in MF-HSCs, these CPT micelles nicely inhibited the HIF-1α and a series of glycolytic players in MF-HSCs and prominently suppressed their proliferation and MF phenotypic characteristics. Accordingly, on in vitro administration to the mice challenged by CCl4 or subjected to bile duct ligation, these VA-decorated CPT micelles ameliorated the pathological symptoms of the livers, as evidenced by the significant reduction in serum levels of ALT and AST, infiltration of inflammatory cells, and collagen accumulation, the drastic down-regulation of multiple fibrotic genes, and the good recovery of attenuated hepatocyte CYP2E1 and lipogenesis regulator PPARγ. Overall, the CPT carried by VA-decorated PEG-PCL polymeric micelles can selectively inhibit the glycolysis and expansion of HSCs and thus suppress fibrogenesis, providing an original and effective approach for anti-fibrotic therapy. STATEMENT OF SIGNIFICANCE: Our work introduces an innovative antifibrotic drug system that is developed upon the active targeting of CPT and aims for the fate reversal of HSCs. Through HSC-targeted delivery achieved by PEG-PCL polymeric micelles decorated with vitamin A-derivatives, CPT significantly suppressed the expressions of HIF-1α and glycolytic enzymes in MF-HSCs, as well as their pathologic expansion in mouse livers. It effectively ameliorated chronic liver fibrosis in mice induced by CCl4 injection or BDL and restored the damaged liver structure and function. These compelling findings demonstrate the therapeutic potential of glycolytic HSC-targeting in combating fibrosis and related disorders and thus provide new promise for future clinical management of such prevalent and life-threatening conditions.

Vitamin D Suppresses Hepatic Stellate Cell Activation by Negatively Regulating Glutamine/β-Catenin Metabolism

Regulation Of Hepatic Stellate Cell Proliferation And Activation By Glutamine Metabolism

Antagonizing EZH2 Combined with Vitamin D3 Exerts a Synergistic Role in Anti-Fibrosis Through Bidirectional Effects on Hepatocytes and Hepatic Stellate Cells.

Targeting glutamine metabolism in hepatic stellate cells alleviates liver fibrosis

Vitamin D Receptor Targets Hepatocyte Nuclear Factor 4α and Mediates Protective Effects of Vitamin D in Nonalcoholic Fatty Liver Disease.

Spontaneous Liver Fibrosis Induced by Long Term Dietary Vitamin D Deficiency in Adult Mice is Related to Chronic Inflammation and Enhanced Apoptosis

Antifibrotic effects of hypocalcemic vitamin D analogs in murine and human hepatic stellate cells and in the CCl4 mouse model

Vitamin D receptor attenuates carbon tetrachloride-induced liver fibrosis via downregulation of YAP

Calcitriol Inhibits NaAsO2 Triggered Hepatic Stellate Cells Activation and Extracellular Matrix Oversecretion by Activating Nrf2 Signaling Pathway Through Vitamin D Receptor

Vitamin D Receptor Regulates Liver Regeneration After Partial Hepatectomy in Male Mice

Active Vitamin D Supplementation Alleviates Initiation and Progression of Nonalcoholic Fatty Liver Disease by Repressing the P53 Pathway.

Curcumin Inhibits Hepatic Stellate Cell Activation Via Suppression of Succinate-Associated HIF-1α Induction

NAMPT-mediated NAD+ biosynthesis suppresses activation of hepatic stellate cells and protects against CCl4-induced liver fibrosis in mice

Glial Cell Line-Derived Neurotrophic Factor (GDNF) Mediates Hepatic Stellate Cell Activation Via ALK5/Smad Signalling

Selective inhibition of glycolysis in hepatic stellate cells and suppression of liver fibrogenesis with vitamin A-derivative decorated camptothecin micelles

1,25(OH)2D3 Protects Liver Fibrosis Through Decreasing the Generation of TH17 Cells.

18α-Glycyrrhizin induces apoptosis and suppresses activation of rat hepatic stellate cells.

Vitamin D Controls T Cell Activation: Implication for Causal Association Between Vitamin D Deficiency and Fibrosis in Chronic Hepatitis C

Γδt Cells Suppress Liver Fibrosis Via Strong Cytolysis and Enhanced NK Cell-Mediated Cytotoxicity Against Hepatic Stellate Cells

CAT1 Silencing Inhibits TGF-β1-induced Mouse Hepatic Stellate Cell Activation in Vitro and Hepatic Fibrosis in Vivo.

Amplifying Hepatic L-aspartate Levels Suppresses CCl 4-Induced Liver Fibrosis by Reversing Glucocorticoid Receptor B-mediated Mitochondrial Malfunction